ClinicalTrials.Veeva

Menu
S

StracSkin, PLLC. | Portsmouth, NH

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY4005130
Risankizumab
LY2439821
Ustekinumab
Deucravacitinib
Tirzepatide
Lutikizumab
Ixekizumab
JNJ-77242113

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 8 total trials

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo
Status recently updated

The purpose of this study is to evaluate how well LY4005130 is tolerated and what side effects may occur in participants with non-segmental vitiligo...

Not yet enrolling
Enrolling
Vitiligo
Non-Segmental Vitiligo (NSV)
Drug: Placebo
Drug: LY4005130
Status recently updated

The purpose of this study is to evaluate how well LY4005130 works in participants with severe alopecia areata (hair loss) when compared with placebo,...

Not yet enrolling
Enrolling
Alopecia Areata
Drug: LY4005130
Drug: Placebo

Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in ar...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo
Drug: Lutikizumab

The purpose of this study is to assess the effectiveness and safety of a single dose of IPN10200 compared to placebo (double-blind phase) and how wel...

Enrolling
Moderate to Severe Glabellar Lines
Biological: IPN10200
Biological: Placebo

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participan...

Enrolling
Psoriasis
Overweight or Obesity
Drug: Tirzepatide

A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

Enrolling
Plaque Psoriasis
Drug: Ustekinumab
Drug: Deucravacitinib

Trial sponsors

Lilly logo
AbbVie logo
Bristol-Myers Squibb (BMS) logo
Ipsen logo
Janssen (J&J Innovative Medicine) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems